alexa Re-validation Of BCR-ABL1 Quantitation Method To Meet The International Scale Standards
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Ana Maria Fraga, Melina Gon?alves dos Santos Barth, Danyella Silva Pereira, Vanessa Dionisio Cantagalli, Miguel Mitne-Neto, Maria Carolina Tostes Pintao and Marcos Tadeu dos Santos
Posters: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.003
The BCR-ABL1 fusion gene is the result of a translocation involving chromosomes 9 and 22, and is found in nearly all patients with chronic myeloid leukemia (CML). Depending on the location of the breakpoint, BCR-ABL1 can encode different proteins. The most common is p210 (with 210 kDa), an aberrant tyrosine kinase known to be critical for the disease; its activity is inhibited by imatinib, a selective targeted designed drug, the first clinically available to treat CML. Molecular monitoring during treatment is based on quantitative RT-PCR (qRT-PCR), targeting BCR-ABL1 transcripts in blood. However, variation of the procedures difficults comparison, confuses patients and physicians, and hampers therapeutic conclusions. So, efforts have been made towards standardization of methodology, with the adoption of an International Scale (IS) for reporting BCR-ABL1 results. We offer a qRT-PCR test to measure p210 transcript levels, but since 2013 we have been improving its quality to meet International Scale criteria. Changes already adopted were: (1) reinforcement of best practices for RNA handling; (2) leukocyte isolated from 10 mL of blood; (3) TRIzol? Reagent used for RNA isolation, instead of silica-based columns; (4) automated pipetting system and thermocycler for cDNA synthesis. These modifications resulted in better RNA integrity and quantity, and improved sensitivity, as detection of ABL1 transcripts copy number (used as internal control) augmented 60%. Also, preliminary data indicated that commercially available standard curves provided more consistent results. As a final point, sample exchanges with reference laboratories will generate a specific conversion factor, aligning our reports to the IS.
Ana Maria Fraga has completed her Ph.D in Genetics from University of Sao Paulo, Brazil. She has worked as a Technical Application Scientist at Life Technologies (Thermo Fisher Scientific). She has been working at Grupo Fleury as a researcher since 2013. She has published 8 papers in reputed journals and is a reference in embryonic stem cells research in Brazil.
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version